PEDIATRIC HEMATOLOGY AND ONCOLOGY

Scope & Guideline

Fostering dialogue in the realm of child health and treatment.

Introduction

Welcome to your portal for understanding PEDIATRIC HEMATOLOGY AND ONCOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0888-0018
PublisherTAYLOR & FRANCIS INC
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1984 to 2024
AbbreviationPEDIATR HEMAT ONCOL / Pediatr. Hematol. Oncol.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

Pediatric Hematology and Oncology focuses on the comprehensive understanding and treatment of blood disorders and cancers in children. The journal aims to disseminate innovative research, clinical findings, and reviews that improve the knowledge and practices within this specialized field.
  1. Pediatric Hematology:
    Research on various hematological disorders affecting children, including anemia, sickle cell disease, and hemophilia, with an emphasis on pathophysiology, treatment modalities, and long-term outcomes.
  2. Oncological Studies:
    Focused studies on pediatric cancers, including leukemia, lymphoma, and solid tumors, exploring diagnosis, treatment strategies, clinical trials, and survivorship.
  3. Transplantation and Cellular Therapies:
    Investigation into hematopoietic stem cell transplantation and other cellular therapies as treatment options for pediatric patients with severe hematological malignancies.
  4. Genetic and Molecular Research:
    Studies examining the genetic underpinnings of pediatric diseases, including genetic disorders, cancer predisposition, and the role of molecular markers in treatment responses.
  5. Supportive Care and Quality of Life:
    Research addressing supportive care measures, psychosocial aspects, and quality of life outcomes for pediatric patients and their families throughout treatment and survivorship.
  6. International Health and Disparities:
    Exploration of the challenges and outcomes of pediatric hematology and oncology in low- and middle-income countries, focusing on access to care and treatment disparities.
The journal has seen a rise in interest in several innovative and critical areas of research that reflect the evolving landscape of pediatric hematology and oncology. These emerging themes are crucial in shaping future research directions and clinical practices.
  1. Precision Medicine and Genetic Testing:
    An increasing number of papers focus on the application of genetic testing and precision medicine approaches to tailor treatments for pediatric patients, indicating a significant trend towards personalized healthcare.
  2. Impact of COVID-19 on Pediatric Patients:
    Research examining the effects of the COVID-19 pandemic on pediatric hematology and oncology patients is on the rise, highlighting the need for understanding how global health crises affect care delivery and patient outcomes.
  3. Innovative Supportive Care Strategies:
    Emerging studies are focusing on supportive care interventions, including psychosocial support and palliative care, which are crucial for improving the quality of life for pediatric patients and their families.
  4. Long-Term Outcomes and Survivorship:
    There is a growing emphasis on the long-term health outcomes and survivorship issues faced by pediatric cancer survivors, reflecting a shift towards recognizing the importance of post-treatment quality of life.
  5. International Collaborative Research:
    An increase in multicenter and international studies indicates a trend towards collaborative research efforts, aiming to address global disparities in pediatric cancer care and outcomes.

Declining or Waning

While certain research areas continue to thrive, others appear to be declining in prominence within the journal. This may reflect shifting priorities in pediatric hematology and oncology or changes in research funding and interest.
  1. Traditional Chemotherapy Approaches:
    There seems to be a decrease in studies focusing solely on conventional chemotherapy regimens, as newer targeted therapies and immunotherapies gain more attention in the treatment of pediatric cancers.
  2. Single-Center Studies:
    A noticeable decline in the publication of single-center studies suggests a shift towards multicenter collaborations that provide broader data and insights into treatment outcomes.
  3. Basic Science and Laboratory Studies:
    Research papers focusing on basic science and laboratory methodologies appear to be waning as clinical applications and translational research take precedence, highlighting a move towards practical and immediate clinical relevance.

Similar Journals

Transplantation and Cellular Therapy

Exploring the Future of Transplantation and Cellular Therapies.
Publisher: ELSEVIER SCIENCE INCISSN: 2666-6375Frequency: 12 issues/year

Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.

Leukemia Research Reports

Fostering collaboration for a leukemia-free future.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Hematology Transfusion and Cell Therapy

Innovating the future of blood disorder management.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

CANCER JOURNAL

Empowering Researchers to Combat Cancer Challenges.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

Blood and Lymphatic Cancer-Targets and Therapy

Exploring New Horizons in Cancer Therapy
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Journal of Blood Medicine

Pioneering Discoveries: Shaping the Future of Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

GEMATOLOGIYA I TRANSFUZIOLOGIYA

Connecting Scholars to the Heart of Medical Science
Publisher: MINISTERSTVO ZDRAVOOKHRANENIYAISSN: 0234-5730Frequency: 4 issues/year

GEMATOLOGIYA I TRANSFUZIOLOGIYA is an esteemed journal published by the MINISTERSTVO ZDRAVOOKHRANENIYA in the Russian Federation, focusing on the vital fields of hematology and transfusion medicine. With a rich history dating back to its inception in 1983, the journal plays a significant role in disseminating critical research and advancements in these areas, particularly relevant given the evolving landscape of medical science. As a recognized publication, it is indexed in Scopus and holds a Q4 category ranking in Hematology for 2023, reflecting its niche but important contributions to the field. Researchers, healthcare professionals, and students can look forward to a variety of peer-reviewed articles that not only address contemporary issues but also pave the way for innovative practices in hematology. Although it does not currently offer open access, the journal remains a valuable resource for those seeking to stay informed about the latest findings and developments.

BONE MARROW TRANSPLANTATION

Advancing the Frontiers of Transplantation Science.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

ACTA HAEMATOLOGICA

Exploring the Depths of Hematology with Authority
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

AMERICAN JOURNAL OF HEMATOLOGY

Advancing Hematological Science Through Rigorous Research
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.